Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age

T G Jensen, H Whittle, Camilla Mordhorst, I R Pedersen, Jeppe Thaarup, A Poulsen, Morten Sodemann, M Jakobsen, L Brink, U Gansted

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

In two trials of measles vaccination in Guinea-Bissau, children were randomized to receive either the Edmonston-Zagreb (EZ) virus at age 4-8 months or, as a control group, a standard dose (5000 p.f.u.) of the Schwarz (SW) virus at 9-12 months. In the first trial a medium dose of EZ virus (40,000 p.f.u.) was used and in the later trial a high dose (150,000 p.f.u.). Pre- and postvaccination blood samples were analysed with a haemagglutination inhibition (HAI) test and an enzyme-linked immunosorbent assay (ELISA). For the ELISA the blood samples were collected on filter paper. Of 362 prevaccination specimens, 18 and 55%, respectively, were positive in the ELISA and HAI tests. At 18-20 months, the children who had received the EZ vaccine had a seropositivity of 91% by the ELISA method and one of 89% by the HAI method. The equivalent values for the SW group of children were 100 and 96% respectively. Antibody levels in the EZ group, as measured by either method, were significantly lower than the levels in the SW group. The serological results of the present study suggest that lowering the age at measles vaccination to below 9 months is feasible. However, further studies are needed to determine which virus strain, dosage and age at vaccination will prove to be optimal in countries where severe measles is common before the age of 9 months.
OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind12
Udgave nummer11
Sider (fra-til)1026-31
Antal sider6
ISSN0264-410X
StatusUdgivet - 1994

Fingeraftryk

Guinea-Bissau
Measles
vaccination
enzyme-linked immunosorbent assay
vaccines
Hemagglutination Inhibition Tests
viruses
Measles virus
hemagglutination inhibition test
dosage
Viruses
blood
hemagglutination
seroprevalence
methodology
sampling
Control Groups
antibodies

Citer dette

@article{79c2610ce2dd4c348f40425f4974efab,
title = "Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age",
abstract = "In two trials of measles vaccination in Guinea-Bissau, children were randomized to receive either the Edmonston-Zagreb (EZ) virus at age 4-8 months or, as a control group, a standard dose (5000 p.f.u.) of the Schwarz (SW) virus at 9-12 months. In the first trial a medium dose of EZ virus (40,000 p.f.u.) was used and in the later trial a high dose (150,000 p.f.u.). Pre- and postvaccination blood samples were analysed with a haemagglutination inhibition (HAI) test and an enzyme-linked immunosorbent assay (ELISA). For the ELISA the blood samples were collected on filter paper. Of 362 prevaccination specimens, 18 and 55{\%}, respectively, were positive in the ELISA and HAI tests. At 18-20 months, the children who had received the EZ vaccine had a seropositivity of 91{\%} by the ELISA method and one of 89{\%} by the HAI method. The equivalent values for the SW group of children were 100 and 96{\%} respectively. Antibody levels in the EZ group, as measured by either method, were significantly lower than the levels in the SW group. The serological results of the present study suggest that lowering the age at measles vaccination to below 9 months is feasible. However, further studies are needed to determine which virus strain, dosage and age at vaccination will prove to be optimal in countries where severe measles is common before the age of 9 months.",
keywords = "Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Guinea-Bissau, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Infant, Measles Vaccine, Measles virus",
author = "Jensen, {T G} and H Whittle and Camilla Mordhorst and Pedersen, {I R} and Jeppe Thaarup and A Poulsen and Morten Sodemann and M Jakobsen and L Brink and U Gansted",
year = "1994",
language = "English",
volume = "12",
pages = "1026--31",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "11",

}

Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau : serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age. / Jensen, T G; Whittle, H; Mordhorst, Camilla; Pedersen, I R; Thaarup, Jeppe; Poulsen, A; Sodemann, Morten ; Jakobsen, M; Brink, L; Gansted, U.

I: Vaccine, Bind 12, Nr. 11, 1994, s. 1026-31.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau

T2 - serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age

AU - Jensen, T G

AU - Whittle, H

AU - Mordhorst, Camilla

AU - Pedersen, I R

AU - Thaarup, Jeppe

AU - Poulsen, A

AU - Sodemann, Morten

AU - Jakobsen, M

AU - Brink, L

AU - Gansted, U

PY - 1994

Y1 - 1994

N2 - In two trials of measles vaccination in Guinea-Bissau, children were randomized to receive either the Edmonston-Zagreb (EZ) virus at age 4-8 months or, as a control group, a standard dose (5000 p.f.u.) of the Schwarz (SW) virus at 9-12 months. In the first trial a medium dose of EZ virus (40,000 p.f.u.) was used and in the later trial a high dose (150,000 p.f.u.). Pre- and postvaccination blood samples were analysed with a haemagglutination inhibition (HAI) test and an enzyme-linked immunosorbent assay (ELISA). For the ELISA the blood samples were collected on filter paper. Of 362 prevaccination specimens, 18 and 55%, respectively, were positive in the ELISA and HAI tests. At 18-20 months, the children who had received the EZ vaccine had a seropositivity of 91% by the ELISA method and one of 89% by the HAI method. The equivalent values for the SW group of children were 100 and 96% respectively. Antibody levels in the EZ group, as measured by either method, were significantly lower than the levels in the SW group. The serological results of the present study suggest that lowering the age at measles vaccination to below 9 months is feasible. However, further studies are needed to determine which virus strain, dosage and age at vaccination will prove to be optimal in countries where severe measles is common before the age of 9 months.

AB - In two trials of measles vaccination in Guinea-Bissau, children were randomized to receive either the Edmonston-Zagreb (EZ) virus at age 4-8 months or, as a control group, a standard dose (5000 p.f.u.) of the Schwarz (SW) virus at 9-12 months. In the first trial a medium dose of EZ virus (40,000 p.f.u.) was used and in the later trial a high dose (150,000 p.f.u.). Pre- and postvaccination blood samples were analysed with a haemagglutination inhibition (HAI) test and an enzyme-linked immunosorbent assay (ELISA). For the ELISA the blood samples were collected on filter paper. Of 362 prevaccination specimens, 18 and 55%, respectively, were positive in the ELISA and HAI tests. At 18-20 months, the children who had received the EZ vaccine had a seropositivity of 91% by the ELISA method and one of 89% by the HAI method. The equivalent values for the SW group of children were 100 and 96% respectively. Antibody levels in the EZ group, as measured by either method, were significantly lower than the levels in the SW group. The serological results of the present study suggest that lowering the age at measles vaccination to below 9 months is feasible. However, further studies are needed to determine which virus strain, dosage and age at vaccination will prove to be optimal in countries where severe measles is common before the age of 9 months.

KW - Antibodies, Viral

KW - Enzyme-Linked Immunosorbent Assay

KW - Guinea-Bissau

KW - Hemagglutination Inhibition Tests

KW - Humans

KW - Immunization Schedule

KW - Infant

KW - Measles Vaccine

KW - Measles virus

M3 - Journal article

C2 - 7975843

VL - 12

SP - 1026

EP - 1031

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11

ER -